Additional Disease Opportunities

True North is evaluating the potential therapeutic benefit of TNT009 in patients with a range of antibody-driven diseases based on the dysregulation of the Classical pathway. We anticipate TNT009 to be a treatment option for patients with warm autoimmune hemolytic anemia, antibody-mediated rejection (such as with kidney transplant), bullous pemphigoid (a rare and debilitating skin disease), and other diseases.